الإحصائيات الأساسية
| CIK | 1793294 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to PPD Inc
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| February 8, 2022 |
PPD / PPD Inc / H&F Corporate Investors VII, Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69355F102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 2, 2022 |
PPD / PPD Inc / Abu Dhabi Investment Authority - BENEFICIAL OWNERSHIP - EXIT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Titles of Class of Securities) 69355F102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| December 20, 2021 |
15-12B 1 form15-12b.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39212 PPD, INC. (Exact name of registrant as spe |
|
| December 9, 2021 |
PPD / PPD Inc / Carlyle Group Inc. - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69355F102 (CUSIP |
|
| December 8, 2021 |
As filed with the Securities and Exchange Commission on December 8, 2021 As filed with the Securities and Exchange Commission on December 8, 2021 Registration No. |
|
| December 8, 2021 |
Amended and Restated By-Laws of PPD, Inc. Exhibit 3.2 BY-LAWS OF PPD, INC. ARTICLE I - GENERAL Section 1.1. Offices. The registered office shall be as set forth in the Certificate of Incorporation. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require. Section 1.2. Seal. The seal of th |
|
| December 8, 2021 |
Amended and Restated Certificate of Incorporation of PPD, Inc. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PPD, INC. FIRST: The name of the corporation (hereinafter called the ?Corporation?) is PPD, Inc. SECOND: The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is Capitol Services, Inc. 1675 South State Street, Ste B, Dover, Delaware 19901 and the name of the regi |
|
| December 8, 2021 |
Thermo Fisher Scientific Completes Acquisition of PPD, Inc. Exhibit 99.1 FOR IMMEDIATE DISTRIBUTION Media Contact Information: Ron O?Brien Thermo Fisher Scientific Investor Contact Information: Rafael Tejada Thermo Fisher Scientific Phone: 781-622-1242 Phone: 781-622-1356 E-mail: [email protected] E-mail: [email protected] Thermo Fisher Scientific Completes Acquisition of PPD, Inc. WALTHAM, Mass., (December 8, 2021)?Thermo Fisher Sci |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): December 8, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| November 8, 2021 |
LSAQ / Lifesci Acquisition II Corp / PPD, Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Julia James PPD, Inc. 929 North Front Street Wilmington, North Carolina 28401 (910) 251-0081 (Name, Addr |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39212 PPD, |
|
| October 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): October 27, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation or organization) (Commission |
|
| October 27, 2021 |
PPD Reports Third Quarter and Year-To-Date 2021 Results Exhibit 99.1 PPD Reports Third Quarter and Year-To-Date 2021 Results WILMINGTON, N.C. (October 27, 2021) - PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2021. Highlights ?Net authorizations growth of 12.7% over third quarter 2020 to $1,352.7 million, resulting in a net book-to-bill ratio of 1 |
|
| October 18, 2021 |
Exhibit B Execution Version DIRECTOR NOMINATION AGREEMENT BY AND AMONG LIFESCI ACQUISITION II CORP. |
|
| October 18, 2021 |
Exhibit C Execution Version AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is entered into as of the 6th day of October, 2021, by and among Science 37 Holdings, Inc. |
|
| October 18, 2021 |
LSAQ / Lifesci Acquisition II Corp / PPD, Inc. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* SCIENCE 37 HOLDINGS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 808644108 (CUSIP Number) Julia James PPD, Inc. 929 North Front Street Wilmington, North Carolina 28401 (910) 251-0081 (Name, Address and Te |
|
| October 18, 2021 |
Joint Filing Agreement by and among the Reporting Persons. Exhibit A JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned acknowledge and agree that the Statement on Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of Common Stock, par value $0. |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39212 PPD, Inc. |
|
| July 29, 2021 |
PPD, Inc. 929 North Front Street Wilmington, NC 28401 April 14, 2021 Pre-Closing Holders Re: Investment Portfolio Earn-Out Ladies and Gentlemen: Reference is made to that certain Agreement and Plan of Merger, dated as of April 26, 2017, by and among Eagle Holding Company I, Eagle Holding Company II, LLC, Eagle Reorganization Merger Sub, Inc., Eagle Buyer, Inc. and Jaguar Holding Company I (the ?Sp |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): July 28, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation or organization) (Commission fi |
|
| July 28, 2021 |
PPD Reports Second Quarter and Year-To-Date 2021 Results Exhibit 99.1 PPD Reports Second Quarter and Year-To-Date 2021 Results WILMINGTON, N.C. (July 28, 2021) - PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the second quarter ended June 30, 2021. Highlights ?Net authorizations growth of 58.4% over second quarter 2020 to $1,666.4 million, resulting in a net book-to-bill ratio of 1.55x |
|
| May 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Amendment No. 1 Check the appropriate box: ? Preliminary information statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive information statement PPD, Inc. (Name of R |
|
| May 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary information statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive information statement PPD, Inc. (Name of |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Amendment No. 1 Check the appropriate box: ? Preliminary information statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive information statement PPD, Inc. (Name of R |
|
| May 14, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ? Preliminary information statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive information statement PPD, Inc. (Name of |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39212 PPD, Inc. |
|
| April 28, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): April 23, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| April 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): April 27, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) (IRS |
|
| April 27, 2021 |
PPD Reports First Quarter 2021 Results Exhibit 99.1 PPD Reports First Quarter 2021 Results WILMINGTON, N.C. (April 27, 2021) - PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the first quarter ended March 31, 2021. Highlights ?Net authorizations growth of 39.3% over first quarter 2020 to $1,481.6 million, resulting in a net book-to-bill ratio of 1.46x on a historical ba |
|
| April 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): April 21, 2021 (April 15, 2021) PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State of Incorporation) (Commission File Number) (I |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): April 16, 2021 (April 15, 2021) PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State of Incorporation) (Commission File Number) (I |
|
| April 16, 2021 |
Exhibit 2.1 [EXECUTION VERSION] AGREEMENT AND PLAN OF MERGER dated as of April 15, 2021, among THERMO FISHER SCIENTIFIC INC., POWDER ACQUISITION CORP. and PPD, INC. TABLE OF CONTENTS Page ARTICLE I The Merger SECTION 1.01. The Merger 1 SECTION 1.02. Closing 2 SECTION 1.03. Effective Time 2 SECTION 1.04. Effects of Merger 2 SECTION 1.05. Certificate of Incorporation and Bylaws 2 SECTION 1.06. Direc |
|
| April 15, 2021 |
Exhibit 99.1 News Media Contact Information: Ron O?Brien Investor Contact Information: Rafael Tejada 781-622-1242 781-622-1356 [email protected] [email protected] www.thermofisher.com Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization Further expands service offering to pharma and biotech customers ? Establishes Thermo Fisher as a global |
|
| April 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported): April 15, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State of Incorporation) (Commission File Number) (I.R.S. Employer Id |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| March 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| February 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39212 PPD, Inc. (E |
|
| February 26, 2021 |
Amendment No. 1 to the Johnston Employment Agreement, dated as of December 15, 2016 Exhibit 10.26 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the "Amendment No. 1?), made and entered into this 15th day of December, 2016, effective as of the 1st day of December, 2016 (the "Effective Date?), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the "Company"), and David Johnston (the "Executive"). WHE |
|
| February 26, 2021 |
Form of PSU Grant Notice and Agreement for Employees under the PPD, Inc. 2020 Omnibus Incentive Plan Exhibit 10.43 PERFORMANCE STOCK UNIT GRANT NOTICE UNDER THE PPD, INC. 2020 OMNIBUS INCENTIVE PLAN (Performance-Based Vesting Award) PPD, Inc. (the ?Company?), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the ?Plan?), hereby grants to the Participant set forth below a number of performance-based Restricted Stock Units (?Performance Stock Units?) |
|
| February 26, 2021 |
Amendment No. 2 to the Johnston Employment Agreement, date Exhibit 10.27 EXECUTION VERSION AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 2?), made and entered into this 1st day of April, 2018 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and David M. John |
|
| February 26, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization 0972792 B.C. LTD Canada AbC.R.O., Inc. Virginia Access to Patients, LLC Pennsylvania Acurian, Inc. Delaware APBI Finance Corporation Delaware Applied Bioscience International, LLC Delaware ATP, LLC North Carolina CCBR (Beijing) Company Limited China CCBR Asia Ltd. Hong Kong CENTER FOR CLINICAL |
|
| February 26, 2021 |
A U D I T E D C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S venBio Global Strategic Fund, L. |
|
| February 26, 2021 |
Amendment No. 1 to the Thakral Employment Agreement, dated as of February 23, 2021 Exhibit 10.45 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Amendment No. 1?), made and entered into this 23 day of February, 2021 and shall be effective as of February 1, 2021 (the ?Effective Date?), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the ?Company?), an |
|
| February 26, 2021 |
Exhibit 10.25 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this "Agreement"), dated as of the 22nd day of May, 2013 (the "Effective Date"), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the "Company"), and David Johnston (the "Executive" and, together with the Company, the "Parties") and, |
|
| February 26, 2021 |
Amendment No. 3 to the Johnston Employment Agreement, dated as of February 23, 2021 Exhibit 10.44 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 3?), made and entered into this 23 day of February, 2021 and shall be effective as of February 1, 2021 (the ?Effective Date?), by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (the ?Company?), and David M. Johnston (the ?Executive?). WHE |
|
| February 26, 2021 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER dated as of April 26, 2017 by and among Eagle Holding Company I Eagle Holding Company II, LLC EAGLE REORGANIZATION MERGER SUB, INC. EAGLE BUYER, INC. and JAGUAR HOLDING COMPANY I TABLE OF CONTENTS Page Article I. CERTAIN DEFINITIONS 1 1.1 Definitions 1 1.2 Construction. 13 1.3 Knowledge 14 Article II. REORGANIZATION; THE MERGER; CLOSING 14 |
|
| February 26, 2021 |
U N A U D I T E D C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S venBio Global Strategic Fund, L. |
|
| February 26, 2021 |
Exhibit 10.23 Strictly Confidential Execution Version ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this "Agreement"), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the "Assignor"), Eagle Holding Company I, a Delaware corporation (the "Assignee"), Pharmaceutical Product Development, LLC, a Delaware limited l |
|
| February 26, 2021 |
Exhibit 10.5 Execution Version EAGLE HOLDING COMPANY I 929 FRONT STREET WILMINGTON, NORTH CAROLINA 28401 May 11, 2017 David M. Johnston Dear David: Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the "Stockholders Agreement"), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the "Company"), Carlyle Partners VI Holdings II, L. |
|
| February 26, 2021 |
U N A U D I T E D C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S venBio Global Strategic Fund, L. |
|
| February 23, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): February 23, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| February 23, 2021 |
EX-99.1 Exhibit 99.1 PPD Reports Fourth Quarter and Full Year 2020 Results Provides First Quarter and Full Year 2021 Guidance WILMINGTON, N.C. (February 23, 2021) - PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, today reported its financial results for the fourth quarter and full year ended December 31, 2020. Highlights • Fourth quarter net authorizations of $1,297.6 mil |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69355F102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 12, 2021 |
SC 13G SCHEDULE 13G CUSIP No. 69355F102 Page 1 of 9 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69355F102 (CUSIP Number) December 31, 2020 (Date of the Event Which Requires Filing of this Stateme |
|
| February 12, 2021 |
EX-99 3 d129288dex99.htm EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the i |
|
| February 12, 2021 |
EX-99.A Exhibit 99.A SCHEDULE 13G CUSIP No. 69355F102 Exhibit A Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the U.S. Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other reporting persons on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of Common S |
|
| February 12, 2021 |
Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock of PPD, Inc. |
|
| February 12, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 69 |
|
| February 12, 2021 |
EX-24 2 d129288dex24.htm EX-24 Exhibit 24 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Joanne Cosiol, Anne Frederick, K |
|
| February 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PPD, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Titles of Class of Securities) 69355F102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| January 14, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): January 13, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 14, 2021 |
EX-10.1 Exhibit 10.1 Execution Version CREDIT AGREEMENT DATED AS OF JANUARY 13, 2021 AMONG PPD, INC., AS BORROWER, PPD DEVELOPMENT, L.P., AS CO-BORROWER, JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, COLLATERAL AGENT AND A L/C ISSUER, THE OTHER LENDERS AND L/C ISSUERS PARTY HERETO, AND J.P. MORGAN SECURITIES LLC, BARCLAYS BANK PLC, BOFA SECURITIES, INC., GOLDMAN SACHS BANK USA, MIZUHO BANK, |
|
| January 11, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 11, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): December 7, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 28, 2020 |
Quarterly Report - 10-Q Q3 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39212 PPD, |
|
| October 27, 2020 |
EX-99.1 Exhibit 99.1 PPD Reports Third Quarter and Year to Date 2020 Results Provides Fourth Quarter and Full Year Guidance for Revenue and Adjusted EBITDA WILMINGTON, N.C. (October 27, 2020) – PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today reported its financial results for the third quarter ended September 30, 2020. Highlights • Net authorizations of $1,200.3 mill |
|
| October 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): October 27, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number |
|
| September 18, 2020 |
38,000,000 Shares PPD, Inc. Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-248780 PROSPECTUS 38,000,000 Shares PPD, Inc. Common Stock This is a public offering of shares of common stock of PPD, Inc. The selling stockholders identified in this prospectus are offering 38,000,000 shares of our common stock. We are not selling any shares of common stock under this prospectus and will not receive an |
|
| September 17, 2020 |
PPD Announces Pricing of Secondary Offering of Shares of Common Stock EX-99.1 Exhibit 99.1 PPD Announces Pricing of Secondary Offering of Shares of Common Stock WILMINGTON, N.C. (September 16, 2020) - PPD, Inc. (Nasdaq:PPD) (the “Company”), a leading global contract research organization, today announced the pricing of an underwritten public offering by certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle |
|
| September 17, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): September 16, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 14, 2020 |
CORRESP September 14, 2020 VIA EDGAR Re: PPD, Inc. Registration Statement on Form S-1 File No. 333-248780 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Nick Lamparski Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as Representatives of the several underwriters of the |
|
| September 14, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 PPD, INC. [ • ] Shares of Common Stock Underwriting Agreement [ • ], 2020 Morgan Stanley & Co. LLC Barclays Capital Inc. J.P. Morgan Securities LLC Goldman Sachs & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10 |
|
| September 14, 2020 |
CORRESP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5110 E-mail Address wbrentani@stblaw. |
|
| September 14, 2020 |
PPD Updates Third Quarter 2020 Financial Guidance EX-99.1 Exhibit 99.1 PPD Updates Third Quarter 2020 Financial Guidance WILMINGTON, N.C. (September 14, 2020) - PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today updated its financial guidance for the third quarter ending September 30, 2020. PPD announced that given the exceptional circumstances surrounding COVID-19 and better than anticipated key operating metrics and |
|
| September 14, 2020 |
Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): September 14, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 14, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on September 14, 2020. |
|
| September 14, 2020 |
PPD Announces Secondary Offering of Shares of Common Stock EX-99.2 Exhibit 99.2 PPD Announces Secondary Offering of Shares of Common Stock WILMINGTON, N.C. (September 14, 2020) - PPD, Inc. (Nasdaq:PPD) (the “Company”), a leading global contract research organization, today announced that certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., have commenced an underwritten public offer |
|
| September 14, 2020 |
CORRESP September 14, 2020 VIA EDGAR Re: PPD, Inc. Registration Statement on Form S-1 File No. 333-248780 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Nick Lamparski Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, PPD, Inc. (the “Company”) hereby requests that the effective date of t |
|
| August 5, 2020 |
Quarterly Report - 10-Q Q2 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39212 PPD, Inc. |
|
| August 4, 2020 |
EX-99.1 Exhibit 99.1 PPD Reports Second Quarter and Year to Date 2020 Results Provides Third Quarter Guidance for Revenue and Adjusted EBITDA WILMINGTON, N.C. (August 4, 2020)—PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today reported its financial results for the second quarter ended June 30, 2020. Highlights • Net authorizations of $1,052.2 million, representing 12.4 |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): August 4, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 20, 2020 |
Draft Registration Statement Table of Contents CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C. |
|
| June 5, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): June 5, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 5, 2020 |
EX-4.1 Exhibit 4.1 Execution Version JAGUAR HOLDING COMPANY II and PPD DEVELOPMENT, L.P. as Issuers 4.625% Senior Notes due 2025 5.000% Senior Notes due 2028 INDENTURE Dated as of June 5, 2020 WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.1. Definitions 1 SECTION 1.2. Other Definitions 45 SECTION 1.3. Rules |
|
| May 21, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 21, 2020 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 21, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): May 21, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) (IRS E |
|
| May 21, 2020 |
Exhibit 99.1 Part I Item 1. Business Note: The information contained in this Item has been updated for the changes made to our segment performance measures during the first quarter of 2020 as discussed in the recasted audited consolidated financial statements and notes thereto in Exhibit 99.3 included elsewhere in this Form 8-K which updates our Annual Report on Form 10-K for the year ended Decemb |
|
| May 21, 2020 |
Exhibit 99.2 Part II Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations Note: The information contained in this Item has been updated for the changes made to our segment performance measures during the first quarter of 2020 as discussed in the recasted audited consolidated financial statements and notes thereto in Exhibit 99.3 included elsewhere in this F |
|
| May 21, 2020 |
PPD, Inc. Announces Offering of Senior Notes EX-99.1 Exhibit 99.1 PPD, Inc. Announces Offering of Senior Notes WILMINGTON, N.C. (May 21, 2020) - PPD, Inc. (Nasdaq:PPD) (the “Company”), a leading global contract research organization, today announced that it intends to offer $700 million in aggregate principal amount of senior notes (the “Notes”), subject to market and other conditions. The Notes are expected to be issued by the Company’s ind |
|
| May 21, 2020 |
Exhibit 99.3 Part II Item 8. Financial Statements and Supplementary Data Note: The information contained in this Item includes changes related to our segment performance measures based on changes made during the first quarter of 2020 in how the Chief Operating Decision Maker began assessing performance and making resource allocation decisions. These changes are discussed further in Note 19, “Segme |
|
| May 21, 2020 |
PPD, Inc. Announces Pricing and Upsizing of Senior Notes Offering EX-99.1 Exhibit 99.1 PPD, Inc. Announces Pricing and Upsizing of Senior Notes Offering WILMINGTON, N.C. (May 21, 2020) - PPD, Inc. (Nasdaq:PPD) (the “Company”), a leading global contract research organization, today announced that Jaguar Holding Company II (“Jaguar”) and PPD Development, L.P. (“PPD Development” and, together with Jaguar, the “Co-Issuers”), both indirect wholly-owned subsidiaries o |
|
| May 7, 2020 |
Quarterly Report - 10-Q Q1 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39212 PPD, Inc. |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): May 6, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) (IR |
|
| May 6, 2020 |
PPD Reports First Quarter 2020 Results EX-99.1 Exhibit 99.1 PPD Reports First Quarter 2020 Results WILMINGTON, N.C. (May 6, 2020)—PPD, Inc. (Nasdaq:PPD), a leading global contract research organization, today reported its financial results for the first quarter ended March 31, 2020. Highlights • Net authorizations of $1,063.6 million, representing 8.8% growth over first quarter 2019 and resulting in a net book-to-bill ratio of 1.30x on |
|
| March 5, 2020 |
Description of PPD, Inc.’s Securities Exhibit 4.5 Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Description of Capital Stock As of December 31, 2019, PPD, Inc., a Delaware corporation (the “Company,” “we,” “our” or “us”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value $0.01 per share. The following |
|
| March 5, 2020 |
PPD / PPD, Inc. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39212 PPD, Inc. (E |
|
| March 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): March 4, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| March 4, 2020 |
PPD Reports Fourth Quarter and Full Year 2019 Results Provides Full Year 2020 Guidance EX-99.1 Exhibit 99.1 PPD Reports Fourth Quarter and Full Year 2019 Results Provides Full Year 2020 Guidance WILMINGTON, N.C. (March 4, 2020) - PPD, Inc. (NASDAQ: PPD), a leading global contract research organization, today reported its financial results for the fourth quarter and full year ended December 31, 2019. “Our fourth quarter and full year results reflect solid commercial and financial suc |
|
| February 18, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): February 18, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 18, 2020 |
EX-99.1 Lender Presentation* * Select pages Exhibit 99.1 Disclaimer This presentation contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements, which are subject to risks, uncertainties and assumptions about PPD, Inc. “the (“Company”), may include projections of the Company’s future financial performance, future service offerings, pote |
|
| February 11, 2020 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date Earliest Event reported): February 10, 2020 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39212 45-3806427 (State or other jurisdiction of incorporation) (Commission File |
|
| February 11, 2020 |
Amended and Restated Certificate of Incorporation of PPD, Inc. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PPD, INC. * * * * * The present name of the corporation is PPD, Inc. (the “Corporation”). The Corporation was incorporated under the name “Eagle Holding Company I” by the filing of the Corporation’s original Certificate of Incorporation with the Secretary of State of the State of Delaware on April 13, 2017. This Amended and Re |
|
| February 11, 2020 |
Amended and Restated Bylaws of PPD, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF PPD, INC. * * * * * ARTICLE I Offices SECTION 1.01 Registered Office. The registered office and registered agent of PPD, Inc. (the “Corporation”) shall be as set forth in the Certificate of Incorporation (as defined below). The Corporation may also have offices in such other places in the United States or elsewhere (and may change the Corporation’s |
|
| February 11, 2020 |
Second Amended and Restated Stockholder’s Agreement EX-1.1 Exhibit 1.1 Execution Version SECOND AMENDED AND RESTATED STOCKHOLDERS AGREEMENT AMONG PPD, INC. AND THE STOCKHOLDERS AS DEFINED HEREIN February 10, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1 Certain Defined Terms 2 Section 1.2 Other Defined Terms 12 Section 1.3 Other Definitional and Interpretation Provisions 15 ARTICLE II CORPORATE GOVERNANCE Section 2.1 Boards of Direc |
|
| February 6, 2020 |
60,000,000 Shares PPD, Inc. Common Stock 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-235860 PROSPECTUS 60,000,000 Shares PPD, Inc. Common Stock This is PPD, Inc.’s initial public offering. We are selling 60,000,000 shares of our common stock. The initial public offering price of our common stock is $27.00 per share. Prior to this offering, no public market existed for our common stock. Our common stock h |
|
| February 6, 2020 |
S-8 As filed with the Securities and Exchange Commission on February 6, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 45-3806427 (State or other jurisdiction of incorporation or organization) (I.R.S. Employe |
|
| February 5, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 PPD, Inc. (Exact name of registrant as specified in its charter) Delaware 45-3806427 (State of incorporation or organization) (I.R.S. Employer Identification No.) 929 North Front Street, Wil |
|
| February 3, 2020 |
CORRESP Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5110 E-mail Address wbrentani@stblaw. |
|
| January 27, 2020 |
Exhibit 10.41 Director RSU Award RESTRICTED STOCK UNIT GRANT NOTICE UNDER THE PPD, INC. 2020 OMNIBUS INCENTIVE PLAN PPD, Inc. (the ?Company?), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the ?Plan?), hereby grants to the Participant set forth below the number of Restricted Stock Units set forth below. The Restricted Stock Units are subject to a |
|
| January 27, 2020 |
Form of Restricted Stock Grant Notice and Agreement under the PPD, Inc. 2020 Omnibus Incentive Plan Exhibit 10.40 Employee Restricted Stock Award RESTRICTED STOCK GRANT NOTICE UNDER THE PPD, INC. 2020 OMNIBUS INCENTIVE PLAN (Time-Based Vesting Award) PPD, Inc. (the ?Company?), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the ?Plan?), hereby grants to the Participant set forth below the number of shares of Restricted Stock set forth below. The |
|
| January 27, 2020 |
Form of Underwriting Agreement Exhibit 1.1 PPD, INC. [?] Shares of Common Stock Underwriting Agreement [?], 2020 Barclays Capital Inc. J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 |
|
| January 27, 2020 |
Form of Option Grant Notice and Agreement under the PPD, Inc. 2020 Omnibus Incentive Plan Exhibit 10.39 Employee Option Award OPTION GRANT NOTICE UNDER THE PPD, INC. 2020 OMNIBUS INCENTIVE PLAN PPD, Inc. (the ?Company?), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the ?Plan?), hereby grants to the Participant set forth below the number of Options (each Option representing the right to purchase one share of Common Stock) set forth be |
|
| January 27, 2020 |
As filed with the Securities and Exchange Commission on January 27, 2020. Table of Contents As filed with the Securities and Exchange Commission on January 27, 2020. |
|
| January 27, 2020 |
PPD, Inc. 2020 Omnibus Incentive Plan Exhibit 10.38 PPD, INC. 2020 OMNIBUS INCENTIVE PLAN 1. Purpose. The purpose of the PPD, Inc. 2020 Omnibus Incentive Plan is to provide a means through which the Company and the other members of the Company Group may attract and retain key personnel and to provide a means whereby directors, officers, employees, consultants and advisors of the Company and the other members of the Company Group can a |
|
| January 27, 2020 |
Exhibit 10.42 Employee RSU Award RESTRICTED STOCK UNIT GRANT NOTICE UNDER THE PPD, INC. 2020 OMNIBUS INCENTIVE PLAN (Time-Based Vesting Award) PPD, Inc. (the ?Company?), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the ?Plan?), hereby grants to the Participant set forth below the number of Restricted Stock Units set forth below. The Restricted S |
|
| January 24, 2020 |
CORRESP Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5110 E-mail Address wbrentani@stblaw. |
|
| January 23, 2020 |
CORRESP Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5110 E-mail Address wbrentani@stblaw. |
|
| January 16, 2020 |
Exhibit 10.18 Strictly Confidential Execution Version ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this ?Agreement?), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the ?Assignor?), Eagle Holding Company I, a Delaware corporation (the ?Assignee?), Pharmaceutical Product Development, LLC, a Delaware limited l |
|
| January 16, 2020 |
EXHIBIT 10.12 EXECUTION VERSION AMENDMENT NO. 5 dated as of April 23, 2019 (this ?Amendment?), to the CREDIT AGREEMENT dated as of August 18, 2015, as amended by that certain Amendment No. 1 dated as of May 31, 2016, that certain Amendment No. 2 dated as of November 10, 2016, that certain Amendment No. 3 dated as of May 30, 2017 and that certain Amendment No. 4 dated as of March 29, 2018 (the ?Cre |
|
| January 16, 2020 |
EXHIBIT 10.5 Execution Version EAGLE HOLDING COMPANY I 929 FRONT STREET WILMINGTON, NORTH CAROLINA 28401 May 11, 2017 B. Judd Hartman Dear Judd: Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the ?Stockholders Agreement?), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the ?Company?), Carlyle Partners VI, L.P., a Delaware |
|
| January 16, 2020 |
EXHIBIT 4.2 EXECUTION VERSION JAGUAR HOLDING COMPANY II and PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC as Issuers 6.375% Senior Notes due 2023 INDENTURE Dated as of August 18, 2015 WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.1. Definitions 1 SECTION 1.2. Other Definitions 42 SECTION 1.3. Rules of Construction |
|
| January 16, 2020 |
Form of Stock Certificate for Common Stock Exhibit 4.1 NUMBER COMMON STOCK FORM OF STOCK CERTIFICATE PPD, INC. SHARES COMMON STOCK INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 69355F 102 This certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK PAR VALUE $0.0 EACH OF PPD, INC. transferable only on the books of the Corporation by the holder hereof in person, or |
|
| January 16, 2020 |
Exhibit 10.35 EAGLE HOLDING COMPANY I 2017 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT GRANT NOTICE Unless otherwise defined herein, the terms defined in the Eagle Holding Company I 2017 Equity Incentive Plan, as the same has been or may be amended from time to time in accordance therewith (the ?Plan?), shall have the same defined meanings in this Stock Option Agreement, which includes the terms |
|
| January 16, 2020 |
Exhibit 10.30 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?), dated as of November 26, 2019 and effective as of November 1, 2019 (the ?Effective Date?), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the ?Company?), and Anshul Thakral (the ?Execut |
|
| January 16, 2020 |
Exhibit 10.14 EXECUTION VERSION SUBSIDIARY GUARANTY Dated as of August 18, 2015 among THE GUARANTORS NAMED HEREIN and THE ADDITIONAL GUARANTORS REFERRED TO HEREIN, as Guarantors, and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent and Collateral Agent TABLE OF CONTENTS Page SECTION 1. Guaranty; Limitation of Liability 1 SECTION 2. Guaranty Absolute 2 SECTION 3. Waivers and Acknowl |
|
| January 16, 2020 |
Power of Attorney (included in the signature page to the Registration Statement) Table of Contents As filed with the Securities and Exchange Commission on January 16, 2020. |
|
| January 16, 2020 |
Exhibit 10.34 EAGLE HOLDING COMPANY I 2017 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT GRANT NOTICE Unless otherwise defined herein, the terms defined in the Eagle Holding Company I 2017 Equity Incentive Plan, as the same has been or may be amended from time to time in accordance therewith (the ?Plan?) shall have the same defined meanings in this Stock Option Agreement, which includes the terms i |
|
| January 16, 2020 |
Exhibit 10.16 FORM OF INDEMNIFICATION AGREEMENT This Indemnification Agreement is dated as of , 20 (this ?Agreement?) and is between PPD, Inc. a Delaware corporation (the ?Company?), and [name of director/officer] (?Indemnitee?). Background The Company believes that in order to attract and retain highly competent persons to serve as directors or in other capacities, including as officers, it must |
|
| January 16, 2020 |
CORRESP Simpson Thacher & Bartlett LLP 2475 HANOVER STREET PALO ALTO, CA 94304 TELEPHONE: +1-650-251-5000 FACSIMILE: +1-650-251-5002 Direct Dial Number +1-650-251-5110 E-mail Address wbrentani@stblaw. |
|
| January 16, 2020 |
EXHIBIT 10.10 EXECUTION VERSION AMENDMENT NO. 3 dated as of May 30, 2017 (this ?Amendment?), to the CREDIT AGREEMENT dated as of August 18, 2015, as amended by that certain Amendment No. 1, dated as of May 31, 2016 and that certain Amendment No. 2, dated as of November 10, 2016 (the ?Credit Agreement?), among JAGUAR HOLDING COMPANY II, a Delaware corporation (the ?Parent Borrower?), PHARMACEUTICAL |
|
| January 16, 2020 |
Exhibit 10.13 EXECUTION VERSION HOLDINGS GUARANTY Dated as of August 18, 2015 between JAGUAR HOLDING COMPANY I, as Guarantor and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Administrative Agent TABLE OF CONTENTS Section Page SECTION 1. Guaranty 1 SECTION 2. Guaranty Absolute 2 SECTION 3. Waivers and Acknowledgments 4 SECTION 4. Subrogation 5 SECTION 5. Payments Free and Clear of Taxes, Etc. 6 SECT |
|
| January 16, 2020 |
Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of May 17, 2012 (the ?Effective Date?), is made by and among Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor or permitted assigns thereto, the ?Company?), Jaguar Holding Company I, a Delaware corporation (together with any successor thereto, ?Parent?) |
|
| January 16, 2020 |
EXHIBIT 10.8 EXECUTION VERSION AMENDMENT NO. 1 AMENDMENT NO. 1 dated as of May 31, 2016 (this ?Incremental Amendment?), to the CREDIT AGREEMENT dated as of August 18, 2015 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the ?Credit Agreement?), among JAGUAR HOLDING COMPANY II, a Delaware corporation (the ?Parent Borrower?), PHARMACEUTICAL P |
|
| January 16, 2020 |
EXHIBIT 10.4 Execution Version EAGLE HOLDING COMPANY I 929 FRONT STREET WILMINGTON, NORTH CAROLINA 28401 May 11, 2017 William Sharbaugh Dear William: Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the ?Stockholders Agreement?), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the ?Company?), Carlyle Partners VI Holdings II, |
|
| January 16, 2020 |
Exhibit 10.36 EAGLE HOLDING COMPANY I 2017 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT GRANT NOTICE Unless otherwise defined herein, the terms defined in the Eagle Holding Company I 2017 Equity Incentive Plan, as the same has been or may be amended from time to time in accordance therewith (the ?Plan?), shall have the same defined meanings in this Stock Option Agreement, which includes the terms |
|
| January 16, 2020 |
Eagle Holding Company I 2017 Equity Incentive Plan Exhibit 10.33 Final Version EAGLE HOLDING COMPANY I 2017 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby bett |
|
| January 16, 2020 |
EXHIBIT 10.31 Execution Version AMENDED AND RESTATED CONSULTING SERVICES AGREEMENT This Amended and Restated Consulting Services Agreement (this ?Agreement?), dated as of May 11, 2017, by and between PPD Development, L.P., a Delaware limited partnership (the ?Company?), Carlyle Investment Management L.L.C., a Delaware limited liability company (?Consultant?), and, solely for purposes of Section 1( |
|
| January 16, 2020 |
Amendment No. 1 to the Sharbaugh Employment Agreement, dated as of February 10, 2016 Exhibit 10.22 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 1?), made and entered into this 10th day of February, 2016 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and William J. Sharbaugh (the ? |
|
| January 16, 2020 |
Amendment No. 1 to the Simmons Employment Agreement, dated as of April 1, 2018 Exhibit 10.19 EXECUTION VERSION AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 1?), made and entered into this 1st day of April, 2018 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and David S. Simm |
|
| January 16, 2020 |
Exhibit 10.15 EXECUTION VERSION SECURITY AGREEMENT Dated August 18, 2015 among The Grantors referred to herein, as Grantors and CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Collateral Agent TABLE OF CONTENTS Section Page Section 1. Grant of Security 2 Section 2. Security for Obligations 5 Section 3. Grantors Remain Liable 6 Section 4. Delivery and Control of Security Collateral 6 Section 5. Maintai |
|
| January 16, 2020 |
Form of Amended and Restated Bylaws of PPD, Inc. Exhibit 3.2 FORM OF AMENDED AND RESTATED BYLAWS OF PPD, INC. * * * * * ARTICLE I Offices SECTION 1.01 Registered Office. The registered office and registered agent of PPD, Inc. (the ?Corporation?) shall be as set forth in the Certificate of Incorporation (as defined below). The Corporation may also have offices in such other places in the United States or elsewhere (and may change the Corporation? |
|
| January 16, 2020 |
EXHIBIT 4.3 EXECUTION VERSION EAGLE HOLDING COMPANY II, LLC as Issuer 7.625% / 8.375% Senior PIK Toggle Notes due 2022 INDENTURE Dated as of May 11, 2017 WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.1. Definitions 1 SECTION 1.2. Other Definitions 45 SECTION 1.3. Rules of Construction 46 ARTICLE II THE NOTES |
|
| January 16, 2020 |
Form of Amended and Restated Certificate of Incorporation of PPD, Inc. Exhibit 3.1 FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PPD, INC. * * * * * The present name of the corporation is PPD, Inc. (the ?Corporation?). The Corporation was incorporated under the name ?Eagle Holding Company I? by the filing of the Corporation?s original Certificate of Incorporation with the Secretary of State of the State of Delaware on April 13, 2017. This Amended and R |
|
| January 16, 2020 |
EXHIBIT 10.9 EXECUTION VERSION AMENDMENT NO. 2 AMENDMENT NO. 2 dated as of November 10, 2016 (this ?Incremental Amendment?), to the CREDIT AGREEMENT dated as of August 18, 2015 (as amended by that certain Amendment No. 1, dated as of May 31, 2016, and as further amended, restated, amended and restated, supplemented or otherwise modified prior to the date hereof, the ?Credit Agreement?), among JAGU |
|
| January 16, 2020 |
Amendment No. 1 to the Hartman Employment Agreement, dated as of February 10, 2016 Exhibit 10.26 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 1?), made and entered into this 10th day of February, 2016 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and B. Judd Hartman (the ?Execu |
|
| January 16, 2020 |
Exhibit 10.20 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), entered into on May 2, 2018 and effective for employment as of May 15, 2018 (the ?Effective Date?), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the ?Company?), and Christopher G. Scully (?Executive? and, together with the Co |
|
| January 16, 2020 |
EXHIBIT 10.11 EXECUTION VERSION AMENDMENT NO. 4 dated as of March 29, 2018 (this ?Amendment?), to the CREDIT AGREEMENT dated as of August 18, 2015, as amended by that certain Amendment No. 1, dated as of May 31, 2016, that certain Amendment No. 2, dated as of November 10, 2016 and that certain Amendment No. 3 dated as of May 30, 2017 (the ?Credit Agreement?), among JAGUAR HOLDING COMPANY II, a Del |
|
| January 16, 2020 |
EXHIBIT 10.7 EXECUTION COPY CREDIT AGREEMENT DATED AS OF AUGUST 18, 2015 AMONG JAGUAR HOLDING COMPANY II, AS PARENT BORROWER, PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC, AS SUBSIDIARY BORROWER, JAGUAR HOLDING COMPANY I, AS HOLDINGS, CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT, COLLATERAL AGENT AND A L/C ISSUER, THE OTHER LENDERS AND L/C ISSUERS PARTY HERETO, CREDIT SUISSE SECURIT |
|
| January 16, 2020 |
Exhibit 10.37 EAGLE HOLDING COMPANY I 2017 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT GRANT NOTICE Unless otherwise defined herein, the terms defined in the Eagle Holding Company I 2017 Equity Incentive Plan, as the same has been or may be amended from time to time in accordance therewith (the ?Plan?), shall have the same defined meanings in this Stock Option Agreement, which includes the terms |
|
| January 16, 2020 |
Amendment No. 3 to the Hartman Employment Agreement, dated as of December 18, 2019 Exhibit 10.29 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 3?), made and entered into this 18th day of December, 2019 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and B. Judd Hartman (the ?Execu |
|
| January 16, 2020 |
Amendment No. 2 to the Hartman Employment Agreement, dated as of April 1, 2018 Exhibit 10.28 EXECUTION VERSION AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 2?), made and entered into this 1st day of April, 2018 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and B. Judd Hartm |
|
| January 16, 2020 |
Exhibit 10.25 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of April 10, 2012 (the ?Effective Date?), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the ?Company?), and B. Judd Hartman (the ?Executive? and, together with the Company, the ?Parties?) and, solely with respect to S |
|
| January 16, 2020 |
Amendment No. 2 to the Sharbaugh Employment Agreement, dated as of March 1, 2019 Exhibit 10.24 EXECUTION VERSION AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (the ?Amendment No. 2?), made and entered into this 1st day of March, 2019 (the ?Effective Date?) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the ?Company?), and William J. Sh |
|
| January 16, 2020 |
EXHIBIT 4.4 Execution Version EAGLE HOLDING COMPANY II, LLC as Issuer 7.75% / 8.50% Senior PIK Toggle Notes due 2022 INDENTURE Dated as of May 14, 2019 WILMINGTON TRUST, NATIONAL ASSOCIATION, as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.1. Definitions 1 SECTION 1.2. Other Definitions 44 SECTION 1.3. Rules of Construction 46 ARTICLE II THE NOTES S |
|
| January 16, 2020 |
EXHIBIT 10.6 Execution Version EAGLE HOLDING COMPANY I 929 FRONT STREET WILMINGTON, NORTH CAROLINA 28401 May 11, 2017 Anshul Thakral Dear Anshul: Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the ?Stockholders Agreement?), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the ?Company?), Carlyle Partners VI Holdings II, L.P. |
|
| January 16, 2020 |
EXHIBIT 10.3 EAGLE HOLDING COMPANY I 929 FRONT STREET WILMINGTON, NORTH CAROLINA 28401 May 2, 2018 Christopher G. Scully Dear Chris: Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the ?Stockholders Agreement?), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the ?Company?), Carlyle Partners VI Holdings II, L.P., a Delaware |
|
| January 16, 2020 |
Exhibit 10.27 Strictly Confidential Execution Version ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this ?Agreement?), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the ?Assignor?), Eagle Holding Company I, a Delaware corporation (the ?Assignee?), Pharmaceutical Product Development, LLC, a Delaware limited l |
|
| January 16, 2020 |
Exhibit 10.23 Strictly Confidential Execution Version ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this ?Agreement?), dated as of May 11, 2017, is entered into by and among Jaguar Holding Company I, a Delaware corporation (the ?Assignor?), Eagle Holding Company I, a Delaware corporation (the ?Assignee?), Pharmaceutical Product Development, LLC, a Delaware limited l |
|
| January 16, 2020 |
Exhibit 10.21 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of April 10, 2012 (the ?Effective Date?), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the ?Company?), and William J. Sharbaugh (the ?Executive? and, together with the Company, the ?Parties?) and, s |
|
| January 16, 2020 |
EXHIBIT 10.2 Execution Version EAGLE HOLDING COMPANY I 929 Front Street Wilmington, North Carolina 28401 May 11, 2017 David Simmons Dear David: Reference is made to (i) the Stockholders Agreement, dated as of May 11, 2017 (the ?Stockholders Agreement?), by and among Eagle Holding Company I, a Delaware corporation (together with any successor, the ?Company?), Carlyle Partners VI Holdings II, L.P., |
|
| January 16, 2020 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Registrant Name of Subsidiary Jurisdiction of Incorporation or Organization 0972792 B.C. LTD Canada AbC.R.O., Inc. Virginia Access to Patients, LLC Pennsylvania Acurian, Inc. Delaware APBI Finance Corporation Delaware Applied Bioscience International, LLC Delaware ATP, LLC North Carolina Cambridge Applied Nutrition Toxicology and Biosciences Limited United Kingdom CCBR |
|
| January 16, 2020 |
EXHIBIT 10.32 Execution Version AMENDED AND RESTATED CONSULTING SERVICES AGREEMENT This Amended and Restated Consulting Services Agreement (this ?Agreement?), dated as of May 11, 2017, by and between PPD Development, L.P., a Delaware limited partnership (the ?Company?), Hellman & Friedman LP, a Delaware limited partnership (?Consultant?), and, solely for purposes of Section 1(a), Jaguar Holding Co |
|
| January 16, 2020 |
Exhibit 10.1 FORM OF SECOND AMENDED AND RESTATED STOCKHOLDERS AGREEMENT AMONG PPD, INC. AND THE STOCKHOLDERS AS DEFINED HEREIN , 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1 Certain Defined Terms 5 Section 1.2 Other Defined Terms 15 Section 1.3 Other Definitional and Interpretation Provisions 18 ARTICLE II CORPORATE GOVERNANCE Section 2.1 Boards of Directors 19 Section 2.2 Board C |
|
| January 9, 2020 |
As filed with the Securities and Exchange Commission on January 9, 2020. Table of Contents As filed with the Securities and Exchange Commission on January 9, 2020. |
|
| December 20, 2019 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on December 20, 2019 This draft registration statement has not been filed with the Securities and Exchange Commission and all information herein remains strictly confidential. |
|
| December 20, 2019 |
DRSLTR SIMPSON THACHER & BARTLETT LLP 2475 HANOVER STREET PALO ALTO, C.A. 94304 TELEPHONE: +1-650-251-5000 FACSIMILE +1-650-251-5002 DIRECT DIAL NUMBER (650) 251-5110 E-MAIL ADDRESS [email protected] December 20, 2019 Robert Shapiro Jim Allegretto Daniel Morris Mara Ransom Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: PPD, Inc. |
|
| November 12, 2019 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on November 12, 2019 This draft registration statement has not been filed with the Securities and Exchange Commission and all information herein remains strictly confidential. |
